PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Festag, M. ; Festag, J. ; Fräßle, S.P.* ; Asen, T. ; Sacherl, J. ; Schreiber, S. ; Mück-Häusl, M. ; Busch, D.H.* ; Wisskirchen, K. ; Protzer, U.

Evaluation of a fully human, hepatitis B virus-specific chimeric antigen receptor in an immunocompetent mouse model.

Mol. Ther. 27, 947-959 (2019)
Verlagsversion Postprint DOI PMC
Open Access Green
Chimeric antigen receptor (CAR) T cell therapy is a promising novel therapeutic approach for cancer but also for chronic infection. We have developed a fully human, second-generation CAR directed against the envelope protein of hepatitis B virus on the surface of infected cells (S-CAR). The S-CAR contains a human B cell-derived single-chain antibody fragment and human immunoglobulin G (IgG) spacer, CD28- and CD3-signaling domains that may be immunogenic in mice. Because immunosuppression will worsen the clinical course of chronic hepatitis B, we aimed at developing a preclinical mouse model that is immunocompetent and mimics chronic hepatitis B but nevertheless allows evaluating efficacy and safety of a fully human CAR. The S-CAR grafted on T cells triggered antibody responses in immunocompetent animals, and a co-expressed human-derived safeguard, the truncated epidermal growth factor receptor (EGFRt), even induced B and T cell responses, both limiting the survival of S-CAR-grafted T cells. Total body irradiation and transfer of T cells expressing an analogous, signaling-deficient S-CAR decoy and the safeguard induced immune tolerance toward the human-derived structures. S-CAR T cells transferred after immune recovery persisted and showed long-lasting antiviral effector function. The approach we describe herein will enable preclinical studies of efficacy and safety of fully human CARs in the context of a functional immune system.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
8.402
1.370
21
25
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Aav ; Car ; Hbv ; T Cell Therapy ; Chimeric Antigen Receptor ; Immunocompetent Mice ; Immunotherapy ; Rejection ; Scfv Expression; Car-t-cells; Reactivation; Replication; Mechanisms; Tolerance; Therapy; Cd19; Challenges; Induction; Injection
Sprache englisch
Veröffentlichungsjahr 2019
HGF-Berichtsjahr 2019
ISSN (print) / ISBN 1525-0016
e-ISSN 1525-0024
Zeitschrift Molecular Therapy
Quellenangaben Band: 27, Heft: 5, Seiten: 947-959 Artikelnummer: , Supplement: ,
Verlag Nature Publishing Group
Verlagsort 50 Hampshire St, Floor 5, Cambridge, Ma 02139 Usa
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Virology (VIRO)
POF Topic(s) 30203 - Molecular Targets and Therapies
Forschungsfeld(er) Immune Response and Infection
PSP-Element(e) G-502700-003
DOI 10.1016/j.ymthe.2019.02.001
WOS ID WOS:000467247800009
Scopus ID 85062430787
PubMed ID 30852138
Erfassungsdatum 2019-03-27
[➜Korrektur melden]